View Older Stories View More Recent Stories

Mar 21, 2016 04:01PM Amgen (AMGN) Says 19 Abstracts Will be Presented at ACC
Mar 21, 2016 04:00PM Amgen To Present Repatha® (Evolocumab) Data At ACC.16
Mar 21, 2016 06:22AM Amgen (AMGN), UCB Announce Romosozumab Phase 3 Met Primary Endpoint in Men With Osteoporosis
Mar 21, 2016 01:00AM Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
Mar 16, 2016 02:02PM Amgen (AMGN) Comments Following Repatha Patent Win
Mar 16, 2016 02:00PM Amgen Wins Patent Case On Repatha® (Evolocumab)
Mar 16, 2016 12:33PM Regeneron (REGN) and Sanofi Confirm Negative Praluent Ruling, 'Strongly Disagree' with Verdict (AMGN)
Mar 10, 2016 04:00PM Amgen (AMGN) sBLA for Exapnded Enbrel Use Accepted by FDA
Mar 10, 2016 04:00PM FDA Accepts Amgen's Supplemental Biologics License Application For The Expanded Use Of Enbrel® (Etanercept) To Treat Pediatric Patients With Chronic Severe Plaque Psoriasis
Mar 3, 2016 04:00PM Amgen To Present At The Cowen And Company 36th Annual Health Care Conference
Mar 2, 2016 04:15PM Amgen Announces 2016 Second Quarter Dividend
Mar 1, 2016 04:01PM Amgen (AMGN) Submits sBLA For BLINCYTO
Mar 1, 2016 04:00PM Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab)
Feb 22, 2016 06:21AM Amgen (AMGN), UCB Announce FRAME Phase 3 Met co-Primary Endpoints; One Secondary Endpoint Missed
Feb 22, 2016 01:00AM Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Feb 16, 2016 06:50AM Amgen (AMGN) Announces Aranesp Phase 3 Met Primary Endpoint in MDS Red Blood Cell Transfusion Reduction
Feb 15, 2016 04:00PM Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)
Feb 5, 2016 05:06PM Amgen To Present At The Leerink Partners 5th Annual Global Healthcare Conference
Feb 5, 2016 07:51AM Amgen (AMGN) Announces BLINCYTO Phase 3 TOWER Met Primary Endpoint in r/r B-Cell Precursor ALL
Feb 4, 2016 04:17PM Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Feb 4, 2016 04:01PM Amgen (AMGN) Says Repatha Phase 3 GAUSS-3 Met co-Primary Endpoints
Feb 4, 2016 04:00PM Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Jan 28, 2016 04:00PM Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $10.38
Jan 25, 2016 05:21PM Amgen (AMGN) BLA for ABP 501 Accepted by FDA
Jan 25, 2016 05:20PM FDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501
Jan 25, 2016 04:03PM Amgen Announces Webcast of 2015 Fourth Quarter and Full Year Financial Results
Jan 25, 2016 06:16AM Amgen (AMGN) Announces Vectibix + BSC Phase 3 Met Primary Endpoint
Jan 23, 2016 01:00PM Vectibix® (panitumumab) And Best Supportive Care Improves Overall Survival Compared To Best Supportive Care In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer
Jan 22, 2016 06:18AM Amgen (AMGN) Announces Japanese Approval of Repatha as PCSK9 Inhibitor
Jan 22, 2016 01:00AM Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Jan 21, 2016 04:34PM Amgen (AMGN) Announces FDA Approval of Supplemental Kyprolis Combo NDA in r/r Multiple Myeloma
Jan 21, 2016 04:32PM FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Jan 7, 2016 04:05PM Amgen To Present At The 34th Annual J.P. Morgan Healthcare Conference
Dec 28, 2015 12:30PM Harris & Harris Group (TINY) Announces Receipt of BioVex Group-Related Milestone Payment
Dec 18, 2015 06:56AM Amgen (AMGN) Announces EC Approval of IMLYGIC for Unresectable Melanoma
Dec 18, 2015 01:00AM European Commission Approves Amgen's IMLYGIC™ (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe
Dec 15, 2015 04:00PM Amgen Announces 27 Percent Increase In 2016 First Quarter Dividend
Dec 15, 2015 09:24AM Pre-Open Stock Movers 12/15: (KTOV) (LL) (VRX) Higher; (NEOT) (KMT) (ZOES) Lower (more...)
Dec 14, 2015 04:01PM Amgen (AMGN) Will Reacquire All Prolia, XGEVA, and Vectibix Rights (GSK)
Dec 14, 2015 04:00PM Amgen Reacquires All Product Rights To Prolia® (denosumab), XGEVA® (denosumab) And Vectibix® (panitumumab) From GSK In 48 Countries
Dec 7, 2015 09:01AM Amgen (AMGN) Announces Presentation of Data from Three BLINCYTO Phase 2s at ASH 2015
Dec 7, 2015 09:00AM Amgen Presents Data From Three Trials Evaluating BLINCYTO® (blinatumomab) In Acute Lymphoblastic Leukemia At ASH 2015
Dec 5, 2015 09:00AM New Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis® (Carfilzomib) As Backbone Therapy In Multiple Myeloma
Dec 5, 2015 09:00AM Pivotal Head-To-Head ENDEAVOR Study Results Published in The Lancet Oncology Demonstrate Superiority of Kyprolis® (carfilzomib) Combination Over Velcade® (bortezomib) Combination
Dec 5, 2015 08:45AM Amgen Submits Application In Europe To Expand Indication Of Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
Dec 4, 2015 08:01AM Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma
Dec 4, 2015 02:00AM Amgen's First Biosimilar Marketing Authorization Application Submitted To European Medicines Agency For ABP 501
Nov 25, 2015 04:00PM Amgen's First Biosimilar Biologics License Application For ABP 501 Submitted To U.S. Food And Drug Administration
Nov 24, 2015 02:00AM European Commission Approves Amgen's BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
Nov 23, 2015 08:10AM Amgen Announces Repatha® Preferred Position On CVS Health Commercial Formularies
View More Recent Stories View Older Stories